nifurtimox (Rx)

  • Print
Brand and Other Names:Lampit

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 30mg
  • 120mg
more...

American Trypanosomiasis (Orphan)

Investigational in the United States

Orphan designation for American trypanosomiasis (Chagas Disease)

8-10 mg/kg/day PO divided q6-8hr for 90-120 days 

Dosage Forms & Strengths

tablet

  • 30mg
  • 120mg
more...

American Trypanosomiasis (Orphan)

Investigational in the United States

Orphan designation for American trypanosomiasis (Chagas Disease)

1-10 years: 15-20 mg/kg/day PO divided q8hr 

11-16 years: 12.5-15 mg/kg/day PO divided q8hr x90 days

Next:

Adverse Effects

>10%

Anorexia (50-60% can limit completion of therapy)

Frequency Not Defined

Ataxia

Convulsions

Depression

Fatigue

Headache

Memory impairment

Paresthesia

Sleep disorder

Tremor

Polyneuritis

Weakness

Pruritic dermatitis

Rash

Gastralgia

Vomiting

Myalgia

Pulmonary infiltrates

Pleural effusion (rare)

Previous
Next:

Warnings

Contraindications

Active or history of peripheral neuropathy

Active or history of seizures & cerebral impairment, such as behavioral disorders, epilepsy, or psychoses

Hepatic impairment

Renal impairment

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: no human studies conducted

Lactation: not known if excreted in breast milk

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Reacts with the nucleic acids of the parasite

Inhibits trypanothione reductase, a parasite-specific antioxidant defense enzyme

Pharmacokinetics

Absorption: rapid, from GI tract

Vd: 755.3 +/- 283.8 L

Metabolism: Liver, undergoes nitroreduction involving cytochrome P-450 and P-450 reductase

Half-Life: 2.95 +/- 1.19 hr

Peak Plasma Time: 2 hr

Excreted: Urine

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous